A breakthrough for those with inoperable lung cancer.

Pharmac is funding a new immunotherapy medicine, called infensey for those with New Zealand's deadliest cancer.

It's the first medicine of its kind funded for lung cancer and will be available for anyone to access.

Lung Foundation CEO Philip Hope says this is a massive step forward in the fight against cancer.

He says the drug gives patients diagnosed with stage 3 non-small cell lung cancer a good option when undergoing treatment.

LISTEN ABOVE

A breakthrough for those with inoperable lung cancer.
Pharmac is funding a new immunotherapy medicine, called infensey for those with New Zealand's deadliest cancer.
It's the first medicine of its kind funded for lung cancer and will be available for anyone to access.
Lung Foundation CEO Philip Hope says this is a massive step forward in the fight against cancer.
He says the drug gives patients diagnosed with stage 3 non-small cell lung cancer a good option when undergoing treatment.
LISTEN ABOVE

A fresh and intelligent start to your day - catch the very latest international and domestic news developments, sport, entertainment and business on Early Edition with Ryan Bridge, on Newstalk ZB.

A fresh and intelligent start to your day - catch the very latest international and domestic news developments, sport, entertainment and business on Early Edition with Ryan Bridge, on Newstalk ZB.